Burning Rock Overview
- Year Founded
-
2014
- Status
-
Public
- Employees
-
1,138
- Stock Symbol
-
BNR
- Share Price
-
$0.82
- (As of Friday Closing)
Burning Rock General Information
Description
Burning Rock Biotech Ltd is a cancer diagnostics company. Its products include OncoScreen Plus and ColonCore. The company has developed various cancer detection products, involving tumor targeting, differentiation of benign and malignant tumors, monitoring of small residual lesions, prediction of tumor recurrence progress, and detection of tumor sensitivity. It offers 12 NGS-based cancer therapy selection tests comprising a broad range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer, using both tissue and liquid biopsy samples.
Contact Information
- Unit 601, 6th Floor, Building 3, Phase 2
- No. 7 Helix 4th Road, International Biological Island
- Guangzhou, Guangdong 510300
- China
Burning Rock Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.82 | $0.83 | $0.82 - $3.80 | $85.1M | 103M | 56.6K | -$0.98 |
Burning Rock Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 |
|---|---|---|---|---|
| EV | 2,813 | 104,807 | 755,871 | 2,052,700 |
| Revenue | 79,192 | 83,634 | 78,652 | 62,227 |
| EBITDA | (102,038) | (126,900) | (116,144) | (54,906) |
| Net Income | (100,332) | (144,217) | (123,383) | (58,946) |
| Total Assets | 159,907 | 230,091 | 357,476 | 407,608 |
| Total Debt | 2,617 | 7,361 | 13,600 | 7,176 |
Burning Rock Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Burning Rock Comparisons
Industry
Financing
Details
00000
000000
Burning Rock Competitors (14)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Exact Sciences | Formerly VC-backed | Madison, WI | 0000 | 00.000 | 00000000 | 00.000 |
| 0000000000 0000000 | Formerly VC-backed | Cambridge, MA | 0000 | 00000 | 00000000000 | |
| 0000 00000000 | Venture Capital-Backed | San Diego, CA | 000 | 00000 | 00000000000 | 00000 |
| 00000000 000000 00 | Formerly VC-backed | Baltimore, MD | 000 | 00000 | 000000&0 | 00000 |
| 00000000 000000000 | Private Equity-Backed | Wuxi, China | 00000 | 00000000 |
Burning Rock Executive Team (8)
Burning Rock Board Members (3)
| Name | Representing | Role | Since |
|---|---|---|---|
| Leo Li | Burning Rock | Chief Financial Officer, Finance & Board Member | 000 0000 |
| Wendy Hayes | Self | Board Member | 000 0000 |
| Yusheng Han | Burning Rock | Chief Executive Officer & Chairman | 000 0000 |
Burning Rock Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Burning Rock Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Burning Rock ESG
Risk Overview
Risk Rating
Updated June, 08, 2021
25.96 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.0
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 14,766
Rank
Percentile
Healthcare
Industry
00 of 605
Rank
Percentile
Medical Services
Subindustry
00 of 108
Rank
Percentile
